Experic provides CDMO and clinical trial supply services with capabilities across packaging and finished-dose modalities, including dry powder inhalation (DPI) products. The company operates a state-of-the-art cGMP facility and emphasizes handling of low-dose powders and customer-oriented, white-glove service. Experic offers end-to-end development and manufacturing services intended to accelerate development and commercialization of therapies. The firm said new growth capital will enable enhancement of its manufacturing capabilities and support accelerated international expansion. Management framed the funding as a way to meet growing demand from biopharma customers and to expand technical capabilities. The company is based in Cranbury, N.J., and delivers global clinical trial supply and manufacturing services. Experic provides formulation, development, manufacturing, and analytical services for hard-to-handle powder drug products as well as clinical trial supply and logistics. The company supports every phase of a product’s life cycle from conception to clinical and commercial scale across dosing and packaging formats including tablets, pellets, capsules, and low-dose dry powder inhalation. Experic operates a state-of-the-art Class A cGMP facility in Cranbury, New Jersey. Over the past year it has experienced extraordinary growth in demand for its services. The company emphasizes personalized service and a flexible approach that drives repeat business. Recent capital will be used to expand capabilities, grow the Cranbury facility, hire top talent, and make further capital investments.

Total raised

$14M

Funding rounds

2

Latest round

Series B

Latest activity

Nov 2022